Metformin produces modest but real weight loss, typically in the range of a few kilograms over months to years, and the effect holds across multiple populations including people with and without diabetes. A 2024 meta-analysis of randomized trials in people with obesity but no diabetes found that metformin lowered BMI by roughly half a point compared with placebo, which translates to a few pounds for most people. That is far less dramatic than the results seen with newer injectable weight-loss drugs, but metformin is cheap, widely available, and has decades of safety data behind it. What makes the picture more interesting is how the drug achieves even that modest effect, and how much the results vary depending on who is taking it and why.
How Much Weight Loss to Expect
The best long-term data comes from the Diabetes Prevention Program, a large trial that followed people at high risk for type 2 diabetes for over 15 years. Among participants who lost at least five percent of their body weight in the first year on metformin, the average weight loss stayed between roughly six and eight percent over the following decade and a half. Across all metformin users (not just those with early success), weight loss averaged about two percent below baseline after ten or more years, compared with almost no change in the placebo group.1PubMed Central. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study That durability matters: adherence to metformin was directly linked to how much weight people kept off.2PubMed Central. Long-term Weight Loss with Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
In people with obesity who do not have diabetes, one study found a mean weight loss of about 5.8 kilograms (roughly 13 pounds) with metformin over six months, while controls gained slightly.3PubMed. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity A 2024 systematic review of randomized controlled trials was more conservative, reporting a BMI reduction of about half a point compared with placebo across doses ranging from 500 to 2,550 milligrams per day.4PubMed. The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta-analysis of randomized controlled trials The honest characterization is “modest but favorable,” a phrase that keeps appearing in the research literature for good reason.
Why Metformin Reduces Weight at All
For a drug originally designed to lower blood sugar, metformin’s weight-lowering effect was initially something of a surprise. Researchers have since identified several overlapping mechanisms, and the story keeps getting more detailed.
The pathway that has drawn the most attention involves a hormone called GDF15. Two independent randomized controlled trials showed that metformin raises circulating levels of GDF15, a signaling molecule that acts on a receptor found only in a small region of the brainstem.5Nature. GDF15 mediates the effects of metformin on body weight and energy balance That brainstem region helps regulate appetite and nausea, and when GDF15 activates it, food intake drops. Mouse studies confirmed this: metformin reduced food intake and body weight in normal mice on a high-fat diet, but those effects disappeared entirely in mice genetically unable to produce GDF15.6PubMed. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss Follow-up work traced the source of that extra GDF15 to the kidneys, which respond to metformin by ramping up production of the hormone and releasing it into the bloodstream.7Cell Metabolism. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight
GDF15 is not the whole story, though. Metformin also triggers the release of gut hormones that promote fullness. It increases secretion of GLP-1, the same satiety hormone that newer injectable weight-loss drugs mimic.8PubMed Central. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes Lab work on human gut tissue confirmed that metformin directly stimulates GLP-1 release from intestinal cells. Metformin also boosts secretion of PYY, another appetite-suppressing hormone often released alongside GLP-1 from the same intestinal cells, raising the possibility that these two hormones work together to curb hunger.9The Journal of Clinical Endocrinology & Metabolism. Metformin Triggers PYY Secretion in Human Gut Mucosa
At a cellular level, metformin activates an enzyme called AMPK, which acts like a fuel gauge inside cells. When AMPK is switched on in the liver, it dials down fat production and ramps up fat burning.10PubMed Central. Role of AMP-activated protein kinase in mechanism of metformin action The same enzyme also suppresses the liver’s production of new glucose, which is the drug’s primary blood-sugar-lowering action.11Journal of Biological Chemistry. Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of AMPK Activation and Gluconeogenic Gene Expression Whether AMPK activation directly causes weight loss or mainly shapes how the body handles fuel is still debated, but it probably contributes to the overall metabolic shift.
Changes in the Gut Microbiome
Metformin reshapes the community of bacteria living in your intestines, and that shift may matter for weight. In one trial involving people without diabetes, metformin significantly increased levels of Akkermansia muciniphila, a bacterium associated with better metabolic health and a healthier gut lining.12Open Forum Infectious Diseases. Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota Metformin also boosted butyrate-producing species, which generate a short-chain fatty acid that feeds intestinal cells and helps reduce inflammation. This microbiome remodeling is now considered one of several mechanisms contributing to metformin’s weight effects, alongside the appetite-hormone and cellular-energy pathways.13PubMed Central. Metformin: Mechanisms in Human Obesity and Weight Loss
Ironically, the microbiome changes are also part of why metformin causes gastrointestinal side effects. About a quarter of people taking metformin experience nausea, diarrhea, or stomach cramps, and roughly five percent find these side effects bad enough to stop the drug entirely.14PubMed Central. Metformin: Diverse molecular mechanisms, gastrointestinal effects and overcoming intolerance in type 2 Diabetes Mellitus: A review Starting at a low dose and increasing gradually over weeks usually helps, and extended-release formulations are gentler on the stomach. But if you have heard that metformin “makes you lose weight by making you feel too sick to eat,” that is an oversimplification. The GDF15 pathway does involve the brainstem’s nausea center, so there is a kernel of truth, but the metabolic and hormonal effects operate independently of whether you feel queasy.
Metformin for PCOS-Related Weight Issues
Polycystic ovary syndrome is one of the most common reasons metformin gets prescribed to people who do not have diabetes. PCOS frequently involves insulin resistance, and metformin improves insulin sensitivity, menstrual regularity, and androgen levels in affected women.15PubMed Central. Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges A meta-analysis found that metformin lowered BMI by about half a point compared with placebo in women with PCOS, along with meaningful improvements in insulin resistance and menstrual-cycle length.16European Journal of Endocrinology. The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
That BMI reduction on its own looks underwhelming, but the picture changes when metformin is paired with dietary changes. One study following women with PCOS on a combined metformin-and-diet approach found a stable eight percent weight reduction that held across all four years of follow-up, along with a 50 percent drop in insulin resistance by year two.17PubMed. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome The caveat, as a recent review emphasized, is that metformin is not considered a first-line weight-loss therapy for PCOS on its own. Its real value in this population is improving the metabolic environment that makes weight loss so difficult in the first place.
Countering Antipsychotic-Induced Weight Gain
Some of the most striking evidence for metformin and weight comes from psychiatry. Antipsychotic medications, particularly certain second-generation drugs, can cause rapid and substantial weight gain. A meta-analysis of 12 studies involving over 700 patients found that metformin reduced weight by about 3.3 kilograms compared with placebo in people taking antipsychotics.18PubMed Central. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis When metformin was started at the same time as the antipsychotic rather than added later, it prevented roughly four kilograms of the weight gain that would otherwise have occurred.19PubMed Central. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation
One randomized trial went further, testing metformin alone, lifestyle counseling alone, and the combination. Patients on placebo gained about three kilograms over 12 weeks, while those on metformin alone lost about 3.2 kilograms and those getting both metformin and lifestyle intervention lost 4.7 kilograms.20JAMA. Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial That roughly eight-kilogram swing between placebo and the combined approach is clinically meaningful, and metformin is currently the only pharmacological agent with established guidelines for preventing antipsychotic-related weight gain.
How Metformin Compares to Newer Weight-Loss Drugs
The arrival of semaglutide and tirzepatide has changed the weight-loss conversation dramatically, and it is worth being honest about where metformin stands relative to them. In a pilot study of patients gaining weight on antipsychotics, semaglutide produced about 4.5 kilograms of weight loss over 16 weeks compared with 2.9 kilograms for metformin.21PubMed Central. Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study In broader obesity trials (not limited to this source list), the newer GLP-1 receptor agonists routinely produce weight loss of 10 to 20 percent of body weight, roughly five to ten times what metformin achieves alone.
So why would anyone choose metformin? Cost is a major factor. Metformin is generic and costs pennies per day in most countries, while branded semaglutide and tirzepatide run over a thousand dollars per month without insurance. Metformin is also an oral pill, not an injection, and it has a safety profile studied over more than six decades. For people who need modest metabolic support rather than dramatic weight reduction, or for those who cannot access or afford injectable drugs, metformin remains a practical option. There is also growing interest in combining metformin with newer agents. Real-world data suggest that multidrug approaches combining metformin with GLP-1 agonists and other medications can produce both better blood-sugar control and greater weight loss than any single drug alone.22PubMed Central. Role of Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Orlistat based Multidrug Therapy in Glycemic Control, Weight Loss, and Euglycemia in Diabesity: A Real-World Experience
Metformin and Weight in Children and Adolescents
Pediatric obesity has prompted interest in whether metformin can help younger populations. A systematic review of randomized trials found that metformin reduced BMI by about 1.4 points compared with placebo in children and adolescents with obesity.23Diabetes Care. Metformin for Obesity in Children and Adolescents: A Systematic Review A later review described the effects as “modest but favorable” on both weight and insulin resistance, with a tolerable safety profile.24Pediatrics. Efficacy and Safety of Metformin for Obesity: A Systematic Review The effect is not large enough for metformin to be considered a standalone treatment for childhood obesity, but it may serve as a useful addition for children with insulin resistance or prediabetes where lifestyle changes alone are not sufficient.
Why Results Vary So Much Between People
If you have read online forums about metformin and weight, you have seen the full range: some people report losing 20 or 30 pounds, while others notice nothing at all. Genetics is part of the explanation. Researchers have identified variants in a gene called SLC2A10 that are associated with a poorer response to metformin, though the evidence is still preliminary.25Journal of the Endocrine Society. Variants of SLC2A10 may be Linked to Poor Response to Metformin Other genetic variations affecting the transporter proteins that move metformin into cells have also been linked to differences in blood-sugar response, and those same transporters likely influence weight effects too.
Beyond genetics, the timing of when you take the drug may matter more than previously appreciated. A pharmacokinetics study found that metformin blood levels varied significantly depending on the time of day the dose was taken, driven by daily rhythms in kidney filtration and transporter activity. Individual chronotype (whether you are naturally a morning person or a night owl) also affected how the body processed the drug.26PubMed Central. Significant impact of time-of-day variation on metformin pharmacokinetics Separate mouse research showed that metformin’s ability to lower blood glucose and activate AMPK in the liver varied dramatically with circadian time.27PubMed Central. The Liver Circadian Clock Modulates Biochemical and Physiological Responses to Metformin This is early-stage science, and nobody is yet prescribing metformin at specific clock times for weight-loss purposes, but it hints at why two people taking the same dose can have very different experiences.
Adherence is another underrated variable. The Diabetes Prevention Program data showed that weight loss was directly proportional to how consistently people actually took the drug over the years. Miss doses frequently, and the modest effect gets even more modest.
Metformin During Pregnancy and Effects on Offspring
Metformin is increasingly used during pregnancy, particularly for gestational diabetes, because it is oral, inexpensive, and carries a lower risk of dangerously low blood sugar compared with insulin. Women taking metformin during pregnancy also tend to gain less weight.28PubMed Central. Metformin use in pregnancy: What about long-term effects in offspring? But the drug crosses the placenta, which has raised questions about what it does to the developing baby.
Recent meta-analyses paint a nuanced picture. Babies exposed to metformin in utero tend to be born slightly smaller, but then show accelerated growth after birth and may have a higher BMI in childhood.29PubMed Central. Long-term effects of metformin on offspring health: A review of current evidence and future directions One follow-up study found that infants whose mothers took metformin during pregnancy were heavier than placebo-group infants by their first birthday, even though there had been no weight difference at birth.30Pediatrics. Metformin’s Effect on First-Year Weight Gain: A Follow-up Study The clinical significance of these growth differences is still being worked out, and the data are limited. But it is a reminder that a drug’s weight-related effects can be complex and do not always move in one direction.
The Botanical Origin Nobody Expects
Metformin’s roots are literally herbal. The drug descends from guanidine, a compound found in a European plant called Galega officinalis, also known as goat’s rue or French lilac. The plant was used as a traditional remedy for diabetes symptoms in medieval Europe.31Practical Diabetes International. Metformin: its botanical background In 1918, guanidine was shown to lower blood glucose, and chemists synthesized a family of related compounds. Some were tried as diabetes treatments in the 1920s and 1930s but abandoned due to toxicity and the arrival of insulin. Metformin itself was synthesized during this era but did not enter clinical use until decades later, eventually becoming the most widely prescribed diabetes drug in the world.32PubMed. Metformin: historical overview That long, winding path from folk medicine to a drug taken by hundreds of millions of people is unusual in modern pharmacology, and the fact that researchers are still uncovering new mechanisms more than sixty years after its introduction says something about how much complexity can hide inside a small, cheap molecule.